NT5E and neoplasm: Results from the exploratory biomarker analyses indicated moderate numerical increases in tumour response rates in the experimental versus control arm in patients with high tumoral CD73 expression, and longer PFS in both the experimental and control arms in patients with high CD73 expression compared with those with low CD73 expression.